Tape Application Protocol for Enhanced Scars

NCT ID: NCT07144046

Last Updated: 2025-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-01

Study Completion Date

2028-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

What is the purpose of this study? The Investigators want to find out whether applying Micropore surgical tape to the medial half of the mastectomy scar for 3 months helps improve its appearance after 12 months, compared to no intervention.

Why is this study important? Scars can cause discomfort and affect how people feel about their bodies. The tape is thought to reduce stress on healing skin and possibly lead to a better-looking scar. But The Investigators need strong evidence to know whether it really helps.

How will the study be done?

This is a randomized, observer-blinded trial.

Women having mastectomy are randomly assigned to either receive the tape on half their scar or receive no tape.

A plastic surgeon and a breast surgeon-who do not know which side had tape-will evaluate wounds using photos after 3 and 12 months.

Patients will also rate their scars using a questionnaire (POSAS), giving their personal view on color, thickness, stiffness, and symptoms like itch or pain.

What else are The Investigators looking at?

The Investigators will examine whether the treated half of the scar looks better than the untreated half within the same woman-this helps control for individual skin differences.

The Investigators will also compare treated versus untreated areas across different women to see if there is a consistent benefit.

If the untaped half of scars looks different from control scars, this may suggest differences between the groups that affect results.

What will this study reveal? It will show whether using the tape improves cosmetic outcomes after mastectomy, and whether patients and clinicians agree on how scars heal. The findings may guide better post-surgery care to reduce scars and improve confidence and quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Detailed Description This study is a randomized, observer-blinded, controlled trial investigating whether application of Micropore surgical tape to the medial half of the mastectomy scar for three months results in improved long-term scar appearance compared to no intervention.

Background and Rationale Scarring after mastectomy can negatively affect body image, comfort, and quality of life. Various post-surgical dressings have been proposed to improve scar cosmesis, including paper-based adhesive tapes such as Micropore. The proposed mechanism is that such tapes may provide mechanical support to the healing wound, reduce tension across the incision, and create a stable microenvironment, thereby minimizing scar widening, irregularity, and discoloration.

While tape therapy is widely used in clinical practice, the evidence for its effectiveness in mastectomy scars is limited, and there is no consensus on its benefit in this context. This trial seeks to address this knowledge gap using a blinded photographic evaluation and patient-reported outcome measures.

Study Design

Participants are randomized in a 1:1 ratio to either:

Intervention group: Application of Micropore tape to the medial half of the mastectomy scar for three months, starting approximately three weeks after surgery.

Control group: No application of Micropore tape; the scar remains uncovered after suture removal.

Block randomization in blocks of four will be used to maintain balanced group sizes over the course of enrollment. Randomization will be performed in REDCap, and allocation will occur after written informed consent is obtained.

Blinding Scar assessments will be conducted by two independent observers (a plastic surgeon and a breast surgeon) who are blinded to group allocation. Evaluations are based on standardized photographs taken at 3 and 12 months postoperatively. Medial and lateral halves of each scar will be assessed separately.

The lateral half of the scar in the intervention group is untreated and is expected to be comparable to the entire scar in the control group. Differences in lateral-half scores between groups will be examined to detect any systematic group imbalances.

Outcome Measures

Primary endpoint:

Difference in scar cosmesis at 12 months between intervention and control groups, based on the SCAR scale (observer-rated) and the Patient and Observer Scar Assessment Scale (POSAS, patient-reported component).

Secondary endpoints:

Within-subject difference between medial and lateral halves of the scar (intraindividual comparison).

Change in scores from 3 to 12 months for both observer and patient assessments.

Assessment of potential systematic differences between groups by comparing lateral halves across arms.

Concordance analysis between patient-reported scores (POSAS) and clinician-rated scores (SCAR) to evaluate agreement and identify systematic bias.

Follow-Up and Data Collection

At 3 months:

Standardized photographs

Patient questionnaire (POSAS)

Compliance assessment for the intervention group

At 12 months:

Standardized photographs

Patient questionnaire (POSAS)

Observer ratings (SCAR scale) of medial and lateral halves from photographs

Photographs are taken under standardized conditions: fixed camera distance (100 cm), controlled lighting, neutral background, and frontal plus 45° angled views.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Scar Improvement Cosmetic Outcome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Micropore tape

Micropore covering of the medial half of the scar

Group Type ACTIVE_COMPARATOR

Micropore covering of the medial half of the scar

Intervention Type OTHER

3 months of micropore covering of the medial half of the scar

Control

Standart Practice

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Micropore covering of the medial half of the scar

3 months of micropore covering of the medial half of the scar

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Micropore

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women undergoing mastectomi without primary recontruction
* BMI between 18-5 and 35
* Age between 18 and 80

Exclusion Criteria

* Known bandaid allergy
* In need of Mepilex Border OP after surgery
* Concurrent treatment with systemic steroid treatment or other immunosuppresants
* Post surgical haematoma that requires surgical intervention
* Known tendency to kelloid or hypertrophic scar formation
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Herlev Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gustav Gede Nervil

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gustav Nervil, MD, PhD

Role: STUDY_DIRECTOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gustav Nervil, MD, PhD

Role: CONTACT

+4523711804

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TAPES

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

NPWT Reduction Mammaplasty
NCT06725459 RECRUITING NA
Delayed-Immediate Breast Reconstruction
NCT00473122 COMPLETED PHASE2